Upstream Bio develops verekitug, an experimental antibody drug for severe asthma, nasal polyps and COPD. UPB reports earnings on Wed, Nov 4, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 2 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 14 | JP Morgan | Target raised | Hold | |
| Aug 12 | Truist Securities | Maintained | Buy | |
| Jun 12 | JP Morgan | Downgrade | Hold | |
| Jun 3 | HC Wainwright & Co. | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in UPB in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UPB is in one of them and how their past UPB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered UPB in an article yet. Here's the latest on the wider market.
About Upstream Bio
Upstream Bio is a biotechnology company based in Waltham, Massachusetts, that develops treatments for inflammatory diseases. Its main candidate, verekitug, is a monoclonal antibody that blocks the receptor for a protein called TSLP, which plays a role in immune responses. The company is testing verekitug in clinical trials for severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease. The drug is not yet approved, and its intended patients are people with these lung and airway conditions.
- Headquarters
- Waltham, MA